Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What are the chances that this will happen?
"the Company expects to begin receiving revenue from the commercialization of the flow cytometry service and prostate tests developed as part of the NeoGenomics relationship in early 2017"
NEO Institutional Ownership Now At 79.21%
General Electric Co. acquired a new stake in NeoGenomics during the fourth quarter valued at approximately $118,050,000.
Conversation with Kevin Kowbel (Part 2)
From "edm872" on the Yahoo board:
- Mr. Kowbel believes that HDC can defend its Intellectual Property using several methods, including litigation if necessary, but also through friendlier methods that are less costly but still beneficial to HDC. I firmly believe that Mr. Kowbel will be our first CEO who really pursues - through all avenues - those companies who steal our IP. Like most shareholders it has been painful to watch other companies benefit financially off HDC's technology, but I actually believe that Mr. Kowbel will try to do something about it, as opposed to finding reasons why we can't.
- Overall, I was impressed with our new CEO and felt significant relief following the sudden dismissal of John Norris. I think Kevin Kowbel strongly believes in HDC and that the company can sustain manageable growth with a reasonable cash burn rate. Ultimately, its good to have a CEO whose objective is realizing HDC's potential and improving shareholder value, as opposed to working for a check on the 15th and 30th. I would ask those on this board to forward this message to other shareholders or HDC message boards. Also, I believe this new management will be more open then previous ones so it might be a good idea to contact the company. Best of luck to all.
Conversation with CEO Kevin Kowbel (Part 1)
From "edm872" on the Yahoo board:
As a large shareholder of HDC (@9m shares between family and friends) I was very concerned about the firing of John Norris as it appeared out of the blue, especially following the shareholder's meeting of July 25. Out of concern, I contacted the company and set up a call with Kevin Kowbel, HDC's new CEO. I spent 30 minutes on the phone with Mr. Kowbel and came away quite impressed. I am going to relay several thoughts about our conversation and the company going forward:
- First and foremost, Mr. Kowbel is a shareholder just like us; he is only concerned about the shareholders and shareholder value, not simply picking up a paycheck until the next venture comes along. To prove this, he is working for free, which is what a good CEO does with a start up or a company facing financial issues.
- Mr. Kowbel has owned stock in HDC for @10 years and has intimately followed every step of the company along the way; he knows HDC's business in and out and he has strong ideas to make HDC a more viable entity; I believe that when Mr. Kowbel says something is going to happen he means it, not the lip service previous CEO's have paid us.
- Mr. Kowbel appreciates the obstacles that HDC faces, but he believes that our technology is game-changing and that our relationships with Neogenomics and Lucena Research via SVM Capital are key components of potential success; furthermore, he understands that these relationships need to be mutually beneficial therefore he wants to continue to build healthy relationships with these companies (and others) by being a good partner who listens and asks meaningful questions.
- Mr. Kowbel wants to take better care of the those at HDC who contribute the most to the company's potential success. He pointed out three individuals who continue to play vital roles at HDC and are key contributors to the company: Marty Delmonte, Mark Moore and Hong Zhang. He believes that if, and when, the company is financially secure these men deserve better.
The objectives at hand to stabilize the Company are:
1. Continue our partnership with NeoGenomics. We believe that the development of tests and products are progressing nicely and last week NeoGenomics announced at their conference call expectations for commercialization of tests and products using our technology. We will support this relationship with every opportunity we have to do so. NeoGenomics is the right partner for HDC to be successful in medical arena and we will support NeoGenomics with all our efforts.
2. Develop new partnerships and relationships in the non-medical arena. We are excited about the work that we are doing with SVM Capital. SVM Capital has recently signed a licensing agreement with Lucena Research to expand the SVM Technology further into the financial markets and the Lucena Team is exactly what SVM Capital needs. You can read about this new partner at https://lucenaresearch.com. Like NeoGenomics, Lucena is the right partner, at the right time. We are aggressively looking for similar models for partnering with companies that can help us – now. These are not long, complicated, drawn out processes that take too long to develop, if ever. They will be now and immediate impacts for HDC.
3. Protecting our Intellectual Property. We will identify the best way to stop letting companies use our technology for free. We realize the traditional methods are expensive and the Company does not have the luxury of excess funds to pursue patent infringers these ways. This team has experience and relationships that will be used to stop the bleeding of our technology to those who currently do not compensate us for their use of our patents. One of our new directors, Henry Kaplan, is an experienced patent attorney and has volunteered to be the Chair of the Patent Monetization Committee. He will work with Eleanor Musick and third party law firms to license companies in addition to those that have already paid licensing fees.
From NEO:
"Work also continues on our new plasma and urine-based, NeoSCORETM prostate cancer test. There are two goals for this test, to diagnose the presence of cancer in patients with BPH (benign prostatic hyperplasia), and to distinguish high-grade from low-grade prostate cancer in patients with prostate cancer. We are excited about the potential for this test and currently expect to launch it in the first half of 2014."
New Message from BQ:
Fellow HDC Shareholders,
My purpose in writing this is to inform you of my strong support for HDC's management and Board and to explain the very substantive reasons for this change in my views.
Over the past few weeks, I met with Chairman Joe McKenzie and had conversations with CEO John Norris and other members of management to discuss HDC. Our discussions addressed not only business developments but also the concerns I had very publicly raised in a series of emails that I shared with HDC stockholders and others. Those conversations led to a fuller appreciation on my part of the steps HDC is taking to implement its business strategy. And I believe they also served as a catalyst for a number of very important changes in spending and governance that I felt were essential to getting our Company moving in the right direction.
By now you have probably received HDC's proxy materials and you know that the Annual Meeting is being held in Savannah. I believe this location reflects in part management's determination to become much more transparent and available and responsive to shareholders. You will also see that three new independent directors have been submitted for your approval. I know Rick Winger, Henry Kaplan and Kevin Kowbel personally and spoke with them extensively before they agreed to make themselves available for nomination to the Board. They are all successful men of great integrity and are committed to a philosophy of governance that lodges control of our Company in the hands of the Board and its leadership in the hands of our CEO, John Norris. I am convinced that their diverse careers in business and law will serve shareholders very well as HDC's turnaround gains headway.
One of the major concerns I had expressed both publicly and privately was HDC's unsustainable spending including salaries and consulting fees. I am pleased by the seriousness with which management is approaching the need for continuing and more extensive austerity measures, a decision that definitely "extends our runway". Further, Mr. Norris asked the current Board to extend the initial provisional part of his employment contract by six months so the new Board will be able to review the entirety of his compensation package with fresh eyes. These wise and necessary steps have persuaded me that our Company is now more accurately described as a promising turnaround and is no longer in an in extremis condition.
I now believe that Mr. Norris is the right man in the right job at the right time as HDC's CEO. Everyone I've spoken with inside the Company confirms that he has worked extremely hard to get HDC to where it is in only 5 months. Without him, HDC never would have been able to develop any of the opportunities that now exist with a number of major multinational firms. I am also informed that our director in Japan, Mr. Sumi Takeichi, has been extraordinarily effective in advancing HDC's interests there and Mr. Norris's long friendship and past business dealings with him have been very beneficial to our Company. And I believe that Secretary Norman Mineta would not have joined our Board had Mr. Norris not been able to demonstrate to him the great power of our technology and its transformative and monetization possibilities.
It's impossible to say how things will turn out, but the potential that was always there is still there. Over the last few years, mismanagement cost HDC a great deal not just in terms of money but far more importantly in time wasted and opportunities lost. That's behind us now and I've pledged to do all I can to help advance HDC's interests as management and the Board proceed to implement the business plan. I continue to believe that HDC's pattern discrimination technology adds very significant value when intelligently applied in the right circumstances. In fact, so do the many major companies that continue to infringe on our patents and pay us nothing, something I hope can be addressed soon and about which I have offered some innovative suggestions.
I strongly urge every shareholder to vote FOR all of the candidates for director as well as for the auditor, Hancock Askew. I certainly will and I know other large shareholders who also will. I will be at the Annual Meeting in Savannah on July 25 and think that everyone who can should also attend. This will be a wonderful opportunity to meet with, listen to and vigorously question those charged with trying to rebuild HDC into what it always could have been with the right leadership. Our director-candidates are men of great and diverse accomplishment in their careers and we are fortunate to have people of such caliber willing to represent our interests at such a critical time. If you do attend, after meeting and speaking with these men, I believe you will feel much better than you have for many years that we are now on the right track. And with the right people.
On a personal note, I think it worth pointing out that I did not request nor was I offered any compensation or position of any sort in connection with what I've written here. My family and I are HDC's largest shareholders and my sole motivation in all I have said and done is to help create the conditions that will allow for a significant increase in shareholder value. And that is worth a great deal to all of us.
Finally, please share this email with any of your fellow HDC shareholders whom I may not have in my address book.
Bill Quirk
HDC shareholder
The Real Shareholder Letter:
http://www.sec.gov/Archives/edgar/data/1141788/000118811213001615/ex99-1.htm
The Good News:
"While disappointed with the examiner's decision in the re-examination, the Company draws encouragement from the fact that the Patent Office agreed that all elements of the Company's patented SVM-RFE method are present in the Intel claims. A fundamental principle of patent law is that the addition of one or more elements to a patented claim does not avoid infringement. In this case, Intel merely added a standard computer operation to the Company's SVM-RFE method. Furthermore, possession of a patent on a series of steps does not avoid infringement of a patent covering a subset of those steps."
Just a Matter of Time:
"As a result, the Company is confident that it will prevail and be declared the sole owner of the SVM-RFE method when its claims are compared side-by-side with Intel’s claims."
http://finance.yahoo.com/news/health-discovery-corporation-issues-challenges-131500688.html
LocWolf, Please can you reply with your assessment of the
08-28-2012 Notice of Intent to Issue a Reexam Certificate. TIA
Retinalytics SVM YouTube views slowly increasing to over 380.
Retinalytics Website Upgrade
Looks like a work-in-progress hopefully in preparation for the work-around for the software compatibility glitch.
http://retinalyze.com/
NeoGenomics To Launch SVM Product This Year:
Douglas M. VanOort, the Company's Chairman and CEO, commented:
"In addition, we recently introduced 10-color Flow Cytometry, which makes us one of only a few labs to offer this service on a broad scale."
Under the terms of the NGNM Agreement:
"In addition, NeoGenomics will pay a royalty of 50% of the revenue recognized from any sub-licensing arrangements for the Cytogenetics Interpretation System and the Flow Cytometry System."
NeoGenomics To Launch SVM Product This Year
Douglas M. VanOort, the Company’s Chairman and CEO, commented:
"Finally we continue to invest heavily to develop products using the pattern recognition technologies we licensed from Health Discovery Corp earlier this year, and the early results are quite promising. Indeed, we expect to begin launching the first of several products using this technology later this year.”
http://finance.yahoo.com/news/neogenomic...
Retinalytics SVM Smart Phone App?...Maybe!
Interesting find by icarus6700 on the Raging Bull board:
https://www.elance.com/samples/retinalytics-web-application-php-mysql-android-iphone/46781493/
http://ragingbull.quote.com/mboard/boards.cgi?board=HDVY&read=17316
Note from Bill Quirk:
Here is a post from the Raging Bull Message board by chazzy58 which
includes a note from Bill Quirk who is a major HDC shareholder:
"Greetings to all. Today's selling on higher than normal volume, may give rise to anxiety on the part of some. I don't happen to believe that this necessarily means anything negative. On the contrary, I believe that there is much room for optimism, and I wanted to share a memo that I just received from Bill Quirk in which he imparts his views on our current situation:
"There is no bad news I know of, not even a whisper. My guess is this selling is unrelated to anything HDC is or is not doing; rather it's a portfolio decision on the part of some larger stockholder. Based on my personal knowledge of a number of large shareholders (anywhere from 4-10 million shares), none of them have been selling. My personal view is that good news is far likelier than bad in the near term. (I have zero insight about Intel). It appears the Retinalyze JV is much more commercially successful than anyone thought and that some serious cash might start to be generated by year-end from Retinalyze's 3-week old agreement with Vision Care Direct. If it works for VCD, there's no reason it shouldn't appeal to other similar firms. In the meantime, NeoGenomics is going gangbusters developing new diagnostic tests some of which are based on HDC's SVM technology and which may start to be commercialized as early as this year. Abbott labs is NG's largest investor so there could be a ready pipeline for commercialization.
So here's my thinking, hopefully not wishful. The Retinalyze JV is the "steak" and NeoGenomic's tests are the "sizzle". Money from these two sources is at a 99% margin, i.e. no variable costs for HDC. And revenue is what we need for a decent stock price, or maybe even a lot higher than that. There is zero danger of HDC running out of money any time soon and these two partner companies are run by highly competent and commercially focused businessmen. I'm not selling. Hope this helps."
Bill
http://ragingbull.quote.com/mboard/boards.cgi?board=HDVY&read=17297
Retinalytics SVM-YouTube Presentation Dated 6/5/12:
Hello TC,
Don't know the share count at this time but I believe that many of the warrants he has as a result of the settlement have expired.
Here is an excerpt from the relevant PR:
"Health Discovery Corporation is very pleased to announce that the declaratory judgment lawsuit brought by William F. Quirk, Jr., related to his 32,527,776 warrants issued pursuant to the 2007 Private Placement transaction, and the Company's counterclaim of Mr. Quirk's breach of fiduciary duty, have been settled.
Pursuant to the settlement agreement, Mr. Quirk exchanged his 32,527,776 warrants for 10,000,000 new warrants. The 32,527,776 exchanged warrants consisted of 16,263,888 warrants with an exercise price of $0.14 and 16,263,888 warrants with an exercise price of $.019. The 10,000,000 new warrants consist of three tranches; two of which are for 3,333,333 warrants each and one for 3,333,334 warrants, with strike prices of $0.20, $0.25 and $0.30, and exercise terms of 12 months, 18 months and 24 months, respectively."
http://www.healthdiscoverycorp.com/pr10.php#
I can only hope that he has good cause for his optimism.
Follow-Up Note from Bill Quirk
From chazzy58 on the Raging Bull Board:
"You're welcome guys! Hey, this follow up from Bill Quirk just in:"
"FWIW, I'm increasingly optimistic about HDC's prospects, at long last. I think the Retinalyze JV has a legitimate potential to mushroom with the existing macular degeneration app and accelerate with more apps. I recently learned that retinal analysis can also give early indications of otherwise asymptomatic diseases like Alzheimers and diabetes. Who knew? The good thing is that its ops require little if any HDC involvement, so 50% of all of Retinalyze's net revenue flows through to HDC's bottom line (nice margin …). The NeoGenomics cancer partnership in January was a huge coup for NGNM for true chump change. HDC had to take it because it was the life-saver needed at the time. But if NGNM actually accomplishes what they plan on this year (and beyond), because they have the ability to physically create and market diagnostic tests that HDC never had and never would, this could be a tremendous royalty generator (at 100% profit margin ...) for HDC in 2013 and beyond. And if the Patent Office ever comes back from its siesta and rules conclusively for HDC', the Intel situation could develop very positively."
Bill Quirk
From chazzy58 on the Raging Bull Board:
"You're welcome guys! Hey, this follow up from Bill Quirk just in:"
"FWIW, I'm increasingly optimistic about HDC's prospects, at long last. I think the Retinalyze JV has a legitimate potential to mushroom with the existing macular degeneration app and accelerate with more apps. I recently learned that retinal analysis can also give early indications of otherwise asymptomatic diseases like Alzheimers and diabetes. Who knew? The good thing is that its ops require little if any HDC involvement, so 50% of all of Retinalyze's net revenue flows through to HDC's bottom line (nice margin …). The NeoGenomics cancer partnership in January was a huge coup for NGNM for true chump change. HDC had to take it because it was the life-saver needed at the time. But if NGNM actually accomplishes what they plan on this year (and beyond), because they have the ability to physically create and market diagnostic tests that HDC never had and never would, this could be a tremendous royalty generator (at 100% profit margin ...) for HDC in 2013 and beyond. And if the Patent Office ever comes back from its siesta and rules conclusively for HDC', the Intel situation could develop very positively."
Bill Quirk
http://ragingbull.quote.com/mboard/boards.cgi?board=HDVY&read=17185
Bill Quirk Note About HDC Liquidity
Posted by Chazzy58 on the Raging Bull Board:
Good morning all. This note from Bill Quirk came across my desk and I don't think that he would mind if I share it here. I happen to agree with him on this:
"All,
Following the 10Q release, concern has been raised about HDC's near-term liquidity that I think is unfounded. The fear is HDC would start selling its NeoGenomics shares in July to fund operations, but since NGNM trades only about 35,000 or so shares a day, HDC couldn't sell enough shares fast enough without depressing NGNM's stock price and thus get less. It's in NeoGenomics' interest that selling by HDC not hurt its stock price since they hope for a NASDAQ listing and need a higher stock price. Presumably NGNM itself could buy some or all of the stock or arrange for another party to do so in a private transaction. Abbott Labs already owns 3.5 million NGNM shares. Alternatively, HDC could elect to not sell NGNM stock but rather use it as collateral for a working capital loan (necessarily guaranteed by a third party who would not do so without access to HDC inside information) to fund operations until operating cash flow is (hopefully) generated from Retinalyze or other sources. In my view, HDC won't sell NGNM on the open market because they won't have to and they may not sell it at all or at least not any time soon. Bottom line, in my view HDC has little if any liquidity issues in the near term."
Bill Quirk
http://ragingbull.quote.com/mboard/boards.cgi?board=HDVY&read=17181
Hologic to Buy Gen-Probe for $3.7 Billion
"Hologic Inc. has agreed to acquire test-maker Gen-Probe Inc. for about $3.7 billion in cash, as the health-products company seeks to broaden its diagnostics business. "
http://online.wsj.com/article/SB10001424052702304050304577375662142165788.html?ru=yahoo&mod=yahoo_hs
Retinalyze.com: This site is under development
Maybe an upgrade for the website???
http://www.retinalyze.com/
Douglas M. VanOort, NGNM Chairman and CEO, Comments on HDVY
"We are making good progress in our work with Health Discovery Corporation to develop new cancer genetic tests and new and better ways to perform our current tests as a result of the licensing agreement we entered into earlier this year."
Neogenomics May Lift HDVY Today
NEOGENOMICS, INC.
PRESS RELEASE
NeoGenomics Reports 72% Revenue Growth, 85% Gross Profit Growth and $1.5 Million Increase in Net Income for Q1 2012
Reinstates and Raises Full Year 2012 Revenue Guidance
Ft. Myers, Florida – April 25, 2012 - NeoGenomics, Inc. (NASD OTC QB: NGNM), a leading provider of cancer-focused genetic testing services today reported its results for the first quarter 2012.
First Quarter 2012 Highlights:
• 75% test volume growth
• 72% revenue growth
• 85% gross profit growth
• Adjusted EBITDA of $1.8 million versus $(97,000) in Q1 2011
• Net income of $603,000, or $0.01 per share, versus a net loss of ($893,000), or ($0.02) per share, in Q1 2011
Retinalyze, LLC Begins Enrolling Ophthalmology Practices
Could be the "Black Swawn" application of SVM that Bill Quirk has been dreaming about.
http://finance.yahoo.com/news/retinalyze-llc-begins-enrolling-ophthalmology-120000948.html
Additional Revenue From Retinalyze?...When???
"In addition, we are also in discussions with large Ophthalmology groups and expect to be executing contracts with these physician groups in the very near future."
Thank you Dr. B!!!
http://finance.yahoo.com/news/retinalyze...
Retinalyze: Just The Tip Of The $ceberg
"This is just the tip of the iceberg, with the other modules soon to be released (i.e. diabetes, hypertension, glaucoma, etc), the number of patients Retinalyze, LLC can impact worldwide is absolutely staggering."
Howard Loff, MD
http://finance.yahoo.com/news/retinalyze-llc-enters-exclusive-agreement-150600215.html
Neogenomics to begin development of HDC tests:
"In addition, we plan to significantly expand our molecular and immunohistochemistry test menus, launch the second test under our agreement with Abbott Molecular, and make important investments to begin developing the technology and tests we licensed from Health Discovery Corp."
http://finance.yahoo.com/news/NeoGenomics-Reports-47-prnews-1270613445.html?x=0
Heart of America Contact Lens Society Will See Retinalyze
"HOACLS has always been a proud supporter of the optometric profession and will continue to develop meetings that offer camaraderie, education and innovation to its member doctors
http://www.hoacls.org/Exhibitors.cfm?strLetter=D
Klink, This has already been addressed:
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_H/threadview?m=tm&bn=48335&tof=15&rt=2&frt=2&dir=f&ri=14443&t=c
MelApp in Article in Parade Mag
# 4 MELAPP
Health Discovery
Snap a photo of a mole using MelApp and get a near-instant evaluation of potential melanoma risk. While no substitute for a diagnosis, it can help you decide whether you should see a doctor.
Works with: iPhone, iPod
Price: $1.99
Get it at: App Store
http://www.parade.com/news/intelligence-report/2012/01/22-10-apps-that-could-save-your-life.html
Black Swan SVM Plasma Diagnostic Tests
"NeoGenomics Laboratories has agreed to use its best efforts to commercialize certain products within one year of the date of the License Agreement, subject to two one-year extensions per product if needed, including (and as defined in the License Agreement), a "Plasma Prostate Cancer Test", a "Pancreatic Cancer Test", a "Colon Cancer Test", a "Cytogenetics Interpretation System", and a "Flow Cytometry Interpretation System" (collectively, the "Initial Licensed Products")."
http://biz.yahoo.com/e/120111/ngnm.ob8-k.html
Here's a link to Bill Quirk's vision regarding development of plasma diagnostics posted by Marcel on the Yahoo board:
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_H/threadview?m=tm&bn=48335&tid=14318&mid=14334&tof=10&frt=2
"Neogenomics Is A Solid Bet In Medical Diagnostics"
http://seekingalpha.com/article/318426-neogenomics-is-a-solid-bet-in-medical-diagnostics?source=yahoo
Minefield Getting Bigger
"This minefield of patents covering the SVM-RFE created by Health Discovery Corporation puts the Company in the unique position of being able to control usage of the technology in most countries in which uses of the technology have been reported."
http://finance.yahoo.com/news/Health-Discovery-Corporation-bw-2851202791.html?x=0&.v=1
Favorable Technology Performance Comparisons:
"The genomic biomarkers covered by the claims of HDC's Patent No. 8,008,012 each performs well individually to distinguish prostate cancer from non-cancer (normal and BPH), however, the unique combination of the genomic biomarkers comprising this HDC prostate cancer test produced an overall test accuracy of 89%. By comparison, the PCA3 test for prostate cancer, developed by Gen-Probe Incorporated and commercially on sale in the United States and Europe, has been reported as having an overall test accuracy of around 81%, while overall test accuracy for PSA is only about 47%."
http://finance.yahoo.com/news/Health-Discovery-Corporation-bw-956963473.html?x=0&.v=1
Health Discovery Corporation Announces Issuance of First Patent Covering Prostate Cancer Biomarkers
http://finance.yahoo.com/news/Health-Discovery-Corporation-bw-956963473.html?x=0&.v=1
Mela Sciences gets approvable letter, shares soar
http://www.reuters.com/article/2011/09/26/melasciences-idUSL3E7KQ1T320110926?feedType=RSS&feedName=rbssHealthcareNews&rpc=43
For Bargain Stocks, Check the Patent Office
"One more factor bodes well for patent values: the recent rise of "nonoperating entities," or, less politely, "patent trolls." They grab patent portfolios for the purpose of suing other companies for violations and securing cash settlements.
That is forcing tech firms to scoop up idle patents defensively, creating a seller's market, says Jorge Torres, an intellectual-property lawyer in New York. So patent-stuffed companies might be richer than they look."
http://finance.yahoo.com/news/For-Bargain-Stocks-Check-the-wallstreet-1679848344.html?x=0
If your assumptions are correct, what other inventions have been developed using SVM RFE IP (MelApp?, SVM Capital?, SPM? etc.) and will be impacted by the following outcome:
"Once the interference proceeding begins, HDC will be identified as the “senior party” based on its earlier priority date, which goes back to 2001. As the “junior party”, due to its earliest priority date of August 2005, Intel will have the burden of proving that its date of actual invention was earlier than HDC’s earliest filing date. If Intel is unable to meet this burden, the claims of Intel’s patent will be canceled by the Patent Office."
If your assumptions are correct, what other inventions have been developed using SVM RFE IP (MelApp?, SVM Capital?, SPM? etc.) and will be impacted by the following outcome:
http://www.healthdiscoverycorp.com/pr/aug03_11.html